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Response to immunotherapies and improved survival are
linked to a T cell-inflamed tumor microenvironment,
which is characterized by expression of a chemokine
and type I interferon gene signature and the presence of
CD8+ tumor-infiltrating T cells. In urothelial bladder
cancer, durable responses to PD1-targeted immu-
notherapies have been reported, yet the majority of
patients still do not benefit clinically. To better under-
stand mechanisms of resistance, we profiled somatic
mutations unique to non-T cell-inflamed urothelial
bladder cancers and identified upregulated molecular
pathways. RNA sequencing and exome somatic muta-
tion data from 237 bladder cancers in The Cancer Gen-
ome Atlas were analyzed. We first confirmed that 32%
of urothelial bladder tumors were non-T cell-inflamed
by immune gene expression profiling. This group had
reduced expression of immune inhibitory markers
PDL1, LAG3, FOXP3, TIM3, IDO1, (P < 0.0001, Wil-
coxon test for each) and an absence of CD8+ tumor-
infiltrating T cells (≤1 per 40x field) by immunohisto-
chemistry performed on available samples (P = 0.01,
Fisher’s exact test). Other samples were classified as
either T cell-inflamed (36%) or intermediate (32%). We
detected 56,052 non-synonymous mutations in all sam-
ples affecting 9,717 genes. To investigate the relation-
ship between overall mutational burden and T cell-
inflamed/non-T cell-inflamed tumors, we calculated the
total number of mutations (MAF < 0.01) per sample by
group. We found no difference in mutational density
between groups (P = 0.80, two-sided t-test). We next
evaluated whether mutations in specific genes could be
linked with T cell exclusion. Of the genes mutated in at
least five samples, 24 occurred only in non-T cell-
inflamed tumors (P < 0.05, Fisher’s exact test). The
most common of those genes was FGFR3, which was
mutated in 11 non-T cell-inflamed samples. Lastly, we
applied Ingenuity Pathway Analysis to the subset of
genes significantly upregulated in the non-T cell-
inflamed tumors and found Wnt/b-catenin and peroxi-
some proliferator-activated receptor gamma (PPARG) to
be the most active (P = 0.003 for each). In summary, we
outline the first characterization of urothelial bladder
cancer subtypes by immune gene expression profiling,
and find that mutational burden does not vary between
them. However, specific gene mutations and molecular
oncogenic pathways show a strong correlation with the
non-T cell-inflamed urothelial bladder subtype.
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